Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06700343 · ClinicalTrials.gov registry record · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
A Phase 3 study of Relapsing-remitting Multiple Sclerosis (RRMS), sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
- 20
- Study locations
NCT06700343: Recruiting Phase 3 study of Relapsing-remitting Multiple Sclerosis (RRMS), sponsored by Amgen.
NCT06700343 is a Phase 3 study of Relapsing-remitting Multiple Sclerosis (RRMS) that is actively recruiting participants, run by Amgen. The registered enrollment target is 444 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06700343, a Phase 3 study of Relapsing-remitting Multiple Sclerosis (RRMS), is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).
Conditions Studied
Interventions
- DRUG Ocrelizumab (US)
- DRUG Ocrelizumab (EU)
- DRUG ABP 692
Study Locations (20)
Florida
- Neurology Offices of South Florida - Boca Raton
- Aqualane Clinical Research - Naples
- Knight Neurology - Rockledge
- Premiere Research Institute Palm Beach - West Palm Beach
Colorado
- Mountain Neurological Research Center - Basalt
- Advanced Neurosciences Research, Llc - Fort Collins
Michigan
- Henry Ford Health - Detroit
- Michigan Institute For Neurological Disorders (Glendale Neurological Associates) - Farmington Hills - Farmington
New Jersey
- JFK Medical Center - Edison
- Hackensack Meridian Health - Paramus
Ohio
- Singlepoint Healthcare Opco, LLC - Columbus
- NDx Clinical Research, Inc - Dayton
Alabama
- University of South Alabama - Mobile
Arizona
- Clinical Endpoints, LLC - Scottsdale
California
- Profound Research - Neurology Center of Southern California - Carlsbad
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2027-12-17 |
| Phase | Phase 3 |
What NCT06700343 shows while recruiting
NCT06700343 is an interventional study that assigns participants to a tested intervention. The registered 444 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Relapsing-remitting Multiple Sclerosis (RRMS) appearing as the primary indexed condition, and to 3 interventions - of which Ocrelizumab (US) is the first listed.
NCT06700343 names 20 study sites across 13 states, led by Florida, Colorado, Michigan.
Frequently Asked Questions
What is clinical trial NCT06700343 about?
NCT06700343 is a clinical study titled "Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)". The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppressi...
What is the current status of trial NCT06700343?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2025-01-13. Estimated completion is 2027-12-17.
What conditions does trial NCT06700343 study?
This clinical trial studies the following conditions: Relapsing-remitting Multiple Sclerosis (RRMS).
What interventions are being tested in trial NCT06700343?
The interventions under investigation include: Ocrelizumab (US) (DRUG), Ocrelizumab (EU) (DRUG), ABP 692 (DRUG).
Who is sponsoring clinical trial NCT06700343?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06700343 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing-remitting Multiple Sclerosis (RRMS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06700343's enrollment target sits among peer trials
444 865th of 2000 higher than 1,135 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
- NCT04751435 · 445 participants · NA
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI